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Abstract
Fasting duration has been associated with lower fasting blood glucose levels, but higher 
2-h post-load levels, and research has indicated an adverse effect of ‘weekend behavior’ 
on human metabolism. We investigated associations of fasting duration and weekday 
of examination with glucose, insulin, glucagon and incretin responses to an oral glucose 
tolerance test (OGTT). This cross-sectional study is based on data from the ADDITION-PRO 
study, where 2082 individuals attended a health examination including an OGTT. Linear 
regression analysis was applied to study the associations of overnight fasting duration 
and day of the week with glucose, insulin, glucagon, glucose-dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) responses to an OGTT. We found that 
a 1 h longer fasting duration was associated with 1.7% (95% CI: 0.8,2.5) higher 2-h glucose 
levels, as well as a 3.0% (95% CI: 1.3,4.7) higher GIP and 2.3% (95% CI: 0.3,4.4) higher 
GLP-1 response. Fasting insulin levels were 20.6% (95% CI: 11.2,30.7) higher on Mondays 
compared to the other weekdays, with similar fasting glucose levels (1.7%, 95% CI: 0.0,3.4). 
In this study, longer overnight fasting duration was associated with a worsening of glucose 
tolerance and increased incretin response to oral glucose. We found higher fasting insulin 
levels on Mondays compared to the other days of the week, potentially indicating a 
worsened glucose regulation after the weekend.
Introduction
Glucose metabolism exhibits circadian rhythmicity (1, 2). 
Longer fasting duration before an oral glucose tolerance 
test (OGTT) has been associated with lower fasting glucose 
but higher post-load glucose levels (3). Additionally, the 
time of the day of an OGTT seems to influence the glucose 
response with higher post-load blood glucose levels in 
the afternoon and evening compared to the morning 
(1, 3). The incretin hormones glucagon-like peptide 1 
(GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP) account for a substantial part of the 
insulin secreted after ingestion of glucose (4, 5, 6). It has 
been shown that the incretin effect is impaired in type 2 
diabetes and obesity (5, 7, 8). Also, the secretion of both 
GLP-1 and GIP has been shown to exhibit a circadian 
pattern, with lower levels in the morning and higher 
levels in the late afternoon (9, 10).
The timing of sleep and meals shows variation over 
the week, with other activity patterns in the weekend 
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compared to the weekdays, a term called social jetlag (11, 
12). A large observational study has reported higher energy 
intake and poorer diet quality in weekends compared to 
weekdays (13). Also, studies on the effect of weekday on 
triglyceride levels showed higher triglyceride levels on 
Mondays compared to Fridays (14, 15), indicating an 
acute adverse effect of ‘weekend behavior’ on metabolism. 
‘Weekend behavior’ is the combination of changes in 
dietary intake as well as a shift in sleep schedule in the 
weekends compared to the daily rhythm in the weekdays 
(11, 12, 13). However, knowledge on the role of weekend 
behavior on glucose metabolism and incretin hormone 
response is lacking.
The objectives of the present cross-sectional study 
were to investigate associations of fasting duration and 
weekday of examination with glucose, insulin, glucagon, 
GIP and GLP-1 responses to an OGTT. We hypothesized 
that longer overnight fasting duration was associated 
with greater incretin response and lower fasting levels of 
glucose and insulin. Moreover, we anticipated that glucose 
regulation on Mondays would be worse than on the other 
weekdays because of less healthy ‘weekend behavior’.
Materials and methods
This cross-sectional study was based on data from the 
Danish ADDITION-PRO study. The ADDITION-PRO study 
is nested in the ADDITION-Denmark study, a longitudinal 
risk-stratified cohort study of individuals at high risk of 
type 2 diabetes conducted from 2001 to 2006 (16). A 
subset of the participants from the ADDITION-Denmark 
study was invited to a follow-up health examination 
conducted from 2009 to 2011. The subset included both 
participants with diabetes, impaired glucose tolerance 
and participants at low to high risk of developing type 
2 diabetes assessed by glycaemic status and score on a 
slightly modified version of the Danish diabetes risk 
questionnaire (16, 17). Of the 4188 individuals invited, 
2082 (50%) attended the follow-up examination. The 
ADDITION-PRO study is described in detail elsewhere 
(16). Of the 2082 participants in the ADDITION-PRO 
study, we excluded 336 with known diabetes and 20 who 
had fasted for less than 8 h (minimum required fasting 
duration), leaving 1726 participants for analysis.
The ADDITION-PRO study was conducted in 
accordance with the Helsinki Declaration, and participants 
gave written informed consent before testing. The study 
was approved by the Ethical Committee of the Central 
Denmark Region (No. 20080229).
Biochemical measurements
Blood samples for the measurements of glucose, insulin, 
glucagon, GIP and GLP-1 were drawn in the fasting state 
and 30- and 120-min post-load during a standard 75 g 
OGTT. The participants were asked to fast for a minimum 
of 8 h prior to the test. The timing of their last meal before 
the test was recorded as well as the date and time of the 
test. All OGTTs were performed on weekdays (Monday–
Friday), with 199 participants on Mondays, 914 on 
Tuesdays, 126 on Wednesdays, 318 on Thursdays and 166 
on Fridays. Three participants had missing information 
on weekday of examination and were omitted from the 
weekday analyses.
Glucose and insulin were analysed in the central 
laboratory at the Steno Diabetes Center Copenhagen, 
Gentofte, Denmark. For the glucose measurements, the 
plasma was prepared immediately after collection in 
fluoride-heparin coated tubes, placed on ice and thereafter 
centrifuged at 2200 g for 10 min at 4°C (16). From 2009 
to 2010, glucose was measured using the Hitachi 912 
system (Roche Diagnostics), but gradually in 2010 this 
was changed to the Vitros 5600 Integrated System (Ortho 
Clinical Diagnostics, Illkirch Cedex, France) (16). For 
the insulin measurements, whole blood was incubated 
for 0.5–1.5 h at room temperature, centrifuged for 10 
min at 2200 g and serum samples were analysed with 
an immunoassay (AutoDELFIA, Perkin Elmer) (16). The 
intraassay coefficient of variation was 0.011, and the 
interassay coefficient of variation was 0.036 with serum 
insulin levels of 129 pmol/L (18).
Samples for measurement of glucagon, GIP and GLP-1 
were first stored in a biobank and were after completion 
of the study analysed within 2 months using identical 
quality controls and batches for all reagents (16, 19). 
Plasma stored in the biobank was from blood sampled 
in chilled EDTA coated tubes, put on ice immediately 
and centrifuged within 30 min after collection at 2200 g  
for 10 min at 4°C and stored at −80°C (16). Glucagon 
was measured using radioimmuno assays using a COOH 
terminus which measures intact glucagon; for details 
see Færch et  al. (19). Total plasma GIP and GLP-1 
concentrations (comprising both intact GIP and GLP-1 
and the metabolites GIP(3–42) and GLP-1(9–36)amide, 
respectively) were measured by radioimmuno assays as 
previously described (19). The analytical detection limit 
for GIP and glucagon was 1 pmol/L, and the intraassay 
coefficient of variation was 6.0% and the interassay 
coefficient of variation was 15% (19, 20). The analytical 
detection limit for GLP-1 was 1 pmol/L, the intraassay 
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
https://doi.org/10.1530/EC-20-0009
https://ec.bioscientifica.com © 2020 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 07/16/2020 12:23:07PM
via University of Copenhagen and Kobenhavns Universitet
K K B Clemmensen et al. Glucose regulation, fasting  
and weekday
2819:4
coefficient of variation was 6.0% and the interassay 
coefficient of variation was 1.5% (19).
Calculations
Early and total responses to the OGTT in plasma glucose, 
serum insulin, plasma glucagon, plasma GIP and plasma 
GLP-1 were calculated as total areas under the curves 
(tAUCs) using the trapezoid rule from the basal state to 
30 min (early response, tAUC0–30) and 120 min (total 
response, tAUC0–120). Relative early response (rAUC0–30) was 
calculated as the ratio tAUC0–30/(fasting concentration × 
30 min) and relative total response (rAUC0–120) as 
tAUC0–120/(fasting concentration × 120 min). Thus, the 
rAUC reflects the change in the concentrations of glucose 
and the different hormones relative to the basal (fasting) 
level. The rAUC is always positive and can therefore be 
logarithmically transformed.
The overnight fasting duration was calculated as the 
time between the last meal and the start of the OGTT. 
Weekdays were grouped into Monday (yes/no). Smoking 
status was dichotomized as current smoker vs non-smoker. 
Physical activity energy expenditure was calculated from 
combined accelerometry and heart rate monitoring for 
7 days. A step test was used to assess cardiorespiratory 
fitness (16).
Statistical analysis
Differences in characteristics between day of examination 
were compared with chi-square or t-test. Linear regression 
analysis was used to study the associations of fasting 
duration and weekday of examination with plasma 
levels at 0, 30 and 120 min as well as with early and total 
relative responses of glucose, insulin, glucagon, GIP and 
GLP-1. The analyses were adjusted for age, sex, BMI and 
smoking status as well as weekday or fasting duration, 
respectively. The outcome variables were logarithmically 
transformed before analysis to obtain normally distributed 
model residuals.
R version 3.6.0 was used for the statistical analyses. A 
two-sided ɑ-level of 0.05 was used.
Results
Participant characteristics
Participant characteristics, stratified by weekday 
of examination, are presented in Table 1. 
Participants examined on Mondays were slightly healthier 
than those examined on the other weekdays with 
lower age and HbA1c levels as well as lower BMI and 
waist circumference. The OGTT started between 07:00 
and 10:00 h in the morning for more than 99% of the 
participants, with a median (quartile 1, quartile 3) starting 
time at 08:25 h (07:50 h,08:51 h).
There was a slightly higher proportion of men among 
those who attended (53%) than among non-attendees 
(43%; P < 0.001). Sixty-eight percent of attendees had 
no relatives with diabetes compared to 74% of the non-
attendees (P < 0.001), and a lower proportion of the 
attendees than the non-attendees were normal weight 
(36% vs 40%; P = 0.006). There were no differences in age, 
hypertension and physical inactivity between attendees 
and non-attendees (16).
Fasting duration
The crude and adjusted estimates from the linear regression 
analyses of overnight fasting duration with glucose and 
hormone levels are shown in Table 2. In the adjusted 
analyses, fasting glucose levels were not associated with 
the length of the overnight fast (Table 2, Fig. 1). However, 
a 1 h longer fasting duration was associated with 1.7% 
(95% CI: 0.8,2.5) higher 2-h glucose levels and 3.6% 
(95% CI: 1.4,5.8) higher 2-h insulin levels (Table 2). No 
association between any of the glucagon measures and 
fasting duration was observed (Fig. 1 and Table 2).
With each additional hour of overnight fast, the mean 
fasting levels of GIP were 2.4% (95% CI: −4.1,−0.7) lower 
and fasting GLP-1 levels were 2.9% (95% CI: −5.1,−0.6) 
lower (Fig. 2 and Table 2). Early GIP (rAUC0–30 min) and total 
(rAUC0–120 min) GIP and GLP-1 responses were positively 
associated with fasting duration (Fig. 2 and Table 2).
Weekdays
The differences in fasting levels, rAUC0–30 min and 
rAUC0–120 min for glucose, insulin, glucagon, GIP and 
GLP-1 between Mondays and the other days of the week 
combined are shown in Table 3. Fasting glucose levels 
were almost similar on Mondays compared to the other 
days of the week but the rAUC0–30 min and rAUC0–120 min for 
glucose were lower on Mondays (Table 3). Fasting insulin 
levels were 20.6% (95% CI: 11.2,30.7) higher and 30-min 
insulin levels were 13.1% (95% CI: 2.8,24.4) higher on 
Mondays. rAUC0–120 min of insulin was lower (−8.4%, 
95% CI:−14.7,−1.5, P = 0.017) on Mondays compared with 
the other week days (Table 3). The measures for glucagon, 
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GIP and GLP-1 did not differ between Mondays and the 
other weekdays.
Discussion
We found slightly higher 2-h glucose and insulin levels in 
participants who had a longer overnight fasting duration 
prior to their OGTT. For GIP and GLP-1, 2–3% higher 
response to oral glucose (rAUC0–120) with 1 h longer 
overnight fasting durations were observed. We found 
similar levels of fasting glucose on Mondays compared to 
the other days of the week combined, while fasting insulin 
was found to be 20.6% higher on Mondays, indicating a 
worsened glucose regulation after the weekend.
Comparison with other studies
Our findings partly support previous findings from the 
large British population-based Whitehall II cohort study 
(3), where longer fasting duration was associated with 
higher 2-h post-load glucose levels. That longer fasting 
duration is associated with higher 2-h post-glucose 
load circulating glucose and insulin concentrations 
is not surprising, as the body with prolonged fasting can be 
expected to become more insulin resistant (21). However, 
we did not find an association between fasting duration 
and fasting glucose levels as was found in the Whitehall II 
study (3). One possible explanation for the discrepancy is 
that the Whitehall II study included the time of day of the 
OGTT in their analysis, which attenuated the association 
of fasting duration with fasting glucose levels (3). In the 
present study, the time range of the starting time of the 
OGTT was too short to add information to the analysis. 
In a large primary care-based study of more than 25,000 
individuals, fasting glucose levels were stable when the 
fasting duration exceeded approximately 3 h (22), which 
is in line with our results. Contrary to our findings, a 
study including 1006 women found 4% lower 2-h glucose 
levels for each 3-h increment in fasting duration (23). 
However, in that study, the overnight fasting duration was 
determined by a telephone 24-h dietary recall conducted 
3–10 days after the OGTT (23), which may have been 
associated with risk of recall bias. In our study, a 3 h 
longer fasting duration was associated with a 5.1% higher 
2-h glucose, which is substantial; that is, the 2-h glucose 
would increase from, for example, 6.4 mmol/L (median 
2-h post-load glucose level) to 6.7 mmol/L. There is a lack 
Table 1 Characteristics of the ADDITION-PRO study population by weekday of examination.
Monday Tuesday–Friday P-value
n 199 1524
Men (n (%)) 100 (50) 821 (54) 0.375
Age (years) 64 (7) 66 (7) <0.001
Height (cm) 170 (9) 170 (9) 0.945
BMI (kg/m2) 26.5 (4.1) 27.3 (4.6) 0.020
Waist circumference (cm) 94.2 (13.1) 95.5 (13.0) 0.200
Hip circumference (cm) 100.6 (8.2) 101.7 (9.9) 0.132
Fat percentage 32.0 (7.6) 32.0 (8.4) 0.988
HbA1c (%) 5.6 (0.4) 5.7 (0.4) 0.004
HbA1c (mmol/mol) 38 (5) 39 (5) 0.004
Glucose tolerance status (n (%)) 0.944
 i-IFG 41 (20.6) 293 (19.2) –
 i-IGT 17 (8.5) 117 (7.7) –
 IFG&IGT 19 (9.5) 143 (9.4) –
 Screen detected type 2 diabetes 22 (11.1) 161 (10.6) –
Overnight fasting (h) 11.8 (10.6,12.9) 11.5 (10.3,13.0) 0.450
Time of fasting sample (h:min) 08:06 (07:42,08:48) 08:24 (08:00,08:54) <0.001
PAEE (kJ/kg/day) 34.3 (15.7) 32.3 (15.8) 0.203
CRF (mL O2/kg/min) 30.1 (5.3) 29.9 (5.4) 0.589
Fasting plasma glucose (mmol/L) 6.1 (0.7) 6.0 (0.8) 0.395
Fasting plasma insulin (pmol/L) 52.2 (47.3) 45.4 (32.5) 0.009
Fasting plasma glucagon (pmol/L) 11.8 (8.0) 11.3 (8.1) 0.394
Fasting plasma GLP-1 (pmol/L) 11.8 (6.8) 12.1 (5.9) 0.479
Fasting plasma GIP (pmol/L) 9.7 (5.9) 9.7 (6.1) 0.952
Data are shown as means (s.d.) or median (quartile 1, quartile 3).
CRF, cardiorespiratory fitness; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; IFG, impaired fasting glucose; i-IFG, 
isolated IFG; IGT, impaired glucose tolerance; i-IGT, isolated IGT; PAEE, physical activity energy expenditure.
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of studies investigating associations of overnight fasting 
duration with glucagon, GIP and GLP-1, so our findings 
of lower GIP and GLP-1 levels in response to longer 
fasting duration are novel and need confirmation in 
other populations.
Participants examined on Mondays in the present 
study were slightly younger and had slightly lower BMI 
and HbA1c than those examined on other weekdays, 
so these characteristics are unlikely to explain our 
findings of a slightly worse glucose regulation in those 
examined on Mondays. To our knowledge, no previous 
studies have investigated associations between weekday 
of examination and glucose levels during an OGTT. A 
study on triglyceride levels based on 1.8 million blood 
samples found 5% higher levels on Mondays compared to 
Fridays among out-patients and 1.9% among in-patients, 
suggesting that the effect of weekend behavior is likely 
to be attenuated when hospitalized (14). In a study of 
807 Danish children with up to three different visit days, 
a marker of insulin resistance in the fasting state was 
found to be 35% higher on Mondays compared to Fridays 
(15). These findings are in agreement with our observation 
of 20.6% higher fasting insulin levels and similar fasting 
glucose levels on Mondays. The higher fasting insulin 
levels on Mondays could possibly be due to ‘weekend 
behavior’, but we did not find higher glucose levels as we 
had also hypothesized.
No previous population-based studies have 
investigated associations between weekday of examination 
and GIP and GLP-1 levels. We did not find any differences 
in levels of GIP and GLP-1 on Mondays compared to 
the other days of the week. In general, fasting levels of 
gut hormones including GIP and GLP-1 are not very 
well defined, because the levels are usually close to the 
detection limit of the assays and likely to be influenced by 
non-specific factors, whereas the measured changes after 
glucose or meal ingestion are more likely to represent real 
changes in hormone concentration (24).
Table 2 Back transformed (from log scale) estimates in percent difference for associations between overnight fasting duration 
and glucose, insulin, glucagon, GIP and GLP-1.
Unadjusted Adjusted for age, sex, BMI, smoking status and weekday
n Estimate (%) 95% CI P n Estimate (%) 95%CI P
Plasma glucose
 Fasting 1717 0.0 (−0.4,0.3) 0.844 1706 −0.2 (−0.5,0.1) 0.267
 30 min 1702 0.4 (−0.2,0.9) 0.159 1691 0.2 (−0.3,0.7) 0.488
 120 min 1710 2.0 (1.1,3.9) <0.001 1699 1.7 (0.8,2.5) <0.001
 rAUC0–30 1702 0.2 (0.0,0.5) 0.068 1691 0.2 (0.0,0.5) 0.109
 rAUC0–120 1698 0.9 (0.5,1.3) <0.001 1687 0.8 (0.4,1.2) <0.001
Plasma insulin
 Fasting 1716 1.6 (−0.3,3.4) 0.094 1705 0.7 (−0.9,2.2) 0.400
 30 min 1699 1.3 (−0.6,3.3) 0.172 1688 0.7 (−1.2,2.5) 0.481
 120 min 1708 4.8 (2.3,7.2) <0.001 1697 3.6 (1.4,5.8) 0.001
 rAUC0–30 1698 0.0 (−1.5,1.4) 0.957 1687 0.2 (−1.2,1.6) 0.805
 rAUC0–120 1694 1.2 (−0.2,2.7) 0.084 1683 1.3 (−0.1,2.7) 0.066
Plasma glucagon
 Fasting 1466 0.5 (−1.4,2.5) 0.601 1455 0.3 (−1.8,1.9) 0.967
 30 min 1453 2.0 (0.0,4.0) 0.048 1442 1.0 (−0.8,2.9) 0.278
 120 min 1457 −0.4 (−3.0,2.3) 0.783 1446 −0.8 (−3.4,1.9) 0.553
 rAUC0–30 1450 0.2 (−0.5,1.0) 0.579 1439 0.0 (−0.7,0.8) 0.903
 rAUC0–120 1442 0.2 (−0.9,1.4) 0.720 1431 0.0 (−1.1,1.2) 0.972
Plasma GIP
 Fasting 1402 −2.6 (−4.3,−0.9) 0.003 1391 −2.4 (−4.1,−0.7) 0.006
 30 min 1390 0.5 (−0.9,1.9) 0.511 1380 0.5 (−0.9,1.9) 0.468
 120 min 1394 0.4 (−1.0,1.8) 0.552 1383 0.7 (−0.7,2.0) 0.328
 rAUC0–30 1386 2.7 (1.2,4.3) <0.001 1376 2.6 (1.1,4.1) 0.001
 rAUC0–120 1377 3.0 (1.4,4.7) <0.001 1367 3.0 (1.3,4.7) 0.001
Plasma GLP-1
 Fasting 1464 −2.3 (−4.6,0.0) 0.046 1453 −2.9 (−5.1,−0.6) 0.013
 30 min 1453 −1.5 (−2.5,1.5) 0.601 1442 −0.9 (−2.8,1.0) 0.358
 120 min 1457 −0.8 (−2.4,0.9) 0.380 1446 −0.7 (−2.3,0.9) 0.388
 rAUC0–30 1448 1.4 (−0.5,3.2) 0.149 1437 1.6 (−0.3,3.4) 0.093
 rAUC0–120 1440 1.9 (−0.2,4.0) 0.073 1429 2.3 (0.3,4.4) 0.026
Estimates are per 1 h increase in fasting duration. Linear regression models.
GIP glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; rAUC0–30, relative early response; rAUC0–120, relative total response.
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Strengths and limitations
We had a unique opportunity to assess associations 
of fasting duration and weekday of examination 
with different markers of glucose metabolism in the 
ADDITION-PRO cohort, which included more than 
1700 individuals with data from standardized three-
point OGTTs with measurements of glucose, insulin 
and glucagon as well as the incretins GIP and GLP-1. A 
limitation of the study was that – as is standard for OGTT 
– the participants were instructed to fast for at least 8 h 
prior to the test. Hence, we were not able to investigate 
overnight fasting durations shorter than 8 h. The fasting 
duration interquartile range only spanned a few hours 
in our study population (10.4–13.0 h) which limited 
our ability to conclude anything beyond this fasting 
Figure 1
Relationship between fasting duration and fasting 
levels, rAUC0–30 and rAUC0–120 for glucose (A, B and 
C), insulin (D, E and F) and glucagon (G, H and I), 
respectively, for a hypothetical man (blue lines) 
and woman (red lines) aged 66 years (population 
mean), BMI 27 kg/m2 (population mean), 
non-smoker (most frequent smoking status), not 
on a Monday. Dashed lines show the 95% 
confidence intervals.
Figure 2
Relationship between fasting duration and fasting 
levels, rAUC0–30 and rAUC0–120 for GLP-1 (A, B and 
C) and GIP (D, E and F), respectively, for a 
hypothetical man (blue lines) and woman (red 
lines) aged 66 years (population mean), BMI 27 
kg/m2 (population mean), non-smoker (most 
frequent smoking status), not on a Monday. 
Dashed lines show the 95% confidence intervals.
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duration. However, this is likely to reflect real-life lengths 
of overnight fasting (12), and we believe the results are 
both generalizable and relevant to real-life situations. As 
this is a cross-sectional study, we do not know whether 
the fasting duration on the day of examination reflects 
the habitual overnight fasting durations. The study 
population was sampled specifically to include both 
individuals with low as well as high risk of diabetes; 
this was done to ensure that participants with different 
levels of diabetes risk were included. It consisted only of 
middle-aged and older individuals, and only half of the 
invited individuals participated. The attendees were more 
likely to be men, overweight and to have a family history 
of diabetes (16). We cannot rule out that there are inter-
individual differences in the participants that attended 
ADDITION-PRO on different days of the week, which 
was not explained by the confounders adjusted for 
in the analysis. Nevertheless, differences in clinical 
characteristics are not likely to explain the findings; 
if anything, the health status of those attending 
examination on a Monday was slightly better than those 
examined on the other weekdays. The reason for this 
remains unknown.
A previous study found that the mean age in those 
with a social jetlag of <1 h was 64 years compared to 
57 years in those with a social jetlag ≥1 h (25). Also, 
the increase in total energy intake from weekdays to 
the weekends seems to be more pronounced among 
those aged 18–64 years compared to those aged 
≥65 years (13). Accordingly, the relatively high mean 
age of the participants in the present study might 
translate into less pronounced differences between 
weekday and weekend behavior than would be expected 
in a younger population.
Table 3 Back transformed (from log scale) estimates in percent difference between Mondays vs the other weekdays for glucose, 
insulin, glucagon, GIP and GLP-1.
Unadjusted
Adjusted for age, sex, BMI, smoking status and fasting 
duration
n Estimate (%) 95% CI P n Estimate (%) 95% CI P
Plasma glucose
 Fasting 1718 0.9  (−0.9,2.7) 0.316 1706 1.7  (0.0,3.4) 0.051
 30 min 1703 −2.1  (−4.8,0.7) 0.134 1691 −0.9 (−3.5,1.8) 0.508
 120 min 1711 −5.1  (−9.5,−0.6) 0.028 1699 −2.9  (−7.2,1.5) 0.187
 rAUC0–30 1703 −1.8  (−3.1,−0.5) 0.007 1691 −1.5  (−2.8,−0.2) 0.020
 rAUC0–120 1699 −3.6  (−5.6,−1.6) <0.001 1687 −2.9  (−4.8,−0.9) 0.004
Plasma insulin
 Fasting 1717 14.8 (4.4,26.3) 0.005 1705 20.6 (11.2,30.7) <0.001
 30 min 1700 8.7 (−1.7,20.1) 0.104 1688 13.1  (2.8,24.4) 0.012
 120 min 1709 1.8 (−9.9,15.1) 0.774 1697 9.1 (−2.5,22.1) 0.128
 rAUC0–30 1699 −5.5 (−12.4,2.0) 0.145 1687 −6.4  (−13.1,0.9) 0.084
 rAUC0–120 1695 −8.4 (−14.9,−1.5) 0.019 1683 −8.4  (−14.7,−1.5) 0.017
Plasma glucagon
 Fasting 1467 3.8  (−5.7,14.2) 0.445 1455 6.1 (−3.2,16.2) 0.207
 30 min 1454 −0.8 (−10.1,9.3) 0.864 1442 3.1 (−6.0,13.1) 0.514
 120 min 1458 2.7  (−9.9,17.0) 0.693 1446 5.7  (−7.2,20.5) 0.405
 rAUC0–30 1451 −2.7  (−6.2,1.1) 0.158 1439 −2.0  (−5.6,1.8) 0.299
 rAUC0–120 1443 −1.8  (−7.2,3.9) 0.537 1431 −0.9 (−6.3,4.9) 0.765
Plasma GIP
 Fasting 1403 −1.3  (−9.5,7.8) 0.777 1391 −2.1  (−10.3,6.8) 0.626
 30 min 1391 3.4  (−3.7,11.0) 0.354 1380 4.0  (−3.0,11.6) 0.270
 120 min 1395 3.8  (−3.1,11.2) 0.292 1383 3.6  (−3.0,10.7) 0.296
 rAUC0–30 1387 4.7  (−2.7,12.7) 0.221 1376 5.8  (−1.6,13.9) 0.129
 rAUC–120 1378 5.1  (−3.1,14.1) 0.228 1367 6.3  (−2.0,15.2) 0.139
Plasma GLP-1
 Fasting 1465 −7.4  (−17.4,3.9) 0.193 1453 −3.7  (−14.1,7.9) 0.518
 30 min 1454 −2.3  (−11.6,7.9) 0.646 1442 1.1  (−8.2,11.4) 0.826
 120 min 1458 0.5 (−7.6,9.3) 0.911 1446 2.2 (−5.6,10.6) 0.595
 rAUC0–30 1449 3.4 (−5.5,13.2) 0.464 1437 2.8 (−6.0,12.4) 0.549
 rAUC0–120 1441 6.2 (−4.0,17.6) 0.243 1429 4.7 (−5.1,15.6) 0.359
Linear regression models.
GIP glucose-dependent insulinotropic polypeptide; GLP-1, and glucagon-like peptide 1; rAUC0–30, relative early response; rAUC0–120, relative total response.
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Implications
The basis for prevention of type 2 diabetes among 
overweight individuals at high risk of developing the 
disease is weight loss and increased physical activity 
(26). Since maintaining the initial weight-loss after 
participating in a weight loss program is difficult (27), 
it is important to have multiple tools at one’s disposal 
when recommending lifestyle changes to individuals at 
high risk of diabetes. Restricting the time of eating during 
the day to a shorter time interval has shown potential as 
a weight loss strategy (12). Restricting the daily eating 
window (so-called ‘time-restricted eating’) has been 
shown to lead to reductions in energy intake (12, 28, 29). 
Despite this fact, a randomized cross-over study found 
that insulin sensitivity was improved in response to ‘early 
time-restricted eating’ (eating duration: 6 h/day, dinner 
before 15:00 h) despite no reduction in energy intake 
and body weight (30). The study found no differences 
in glucose concentrations during an OGTT between 
the groups (30). However, recent short-term cross-over 
studies have suggested that ‘early time-restricted eating’ 
with concomitant longer fasting duration is associated 
with improved glucose tolerance during a mixed meal 
test and reductions in fasting glucose concentrations 
(31), as well as in 24-h mean glucose and glycaemic 
variability (32) during continuous glucose monitoring 
despite similar energy intake (32). As we did not see lower 
fasting plasma glucose levels among those with longer 
fasting duration, this can also be used to reassure people 
that their body can maintain a normal blood glucose 
level even after having a longer overnight fast. Late night 
food consumption has been proposed as a risk factor for 
type 2 diabetes and cardiometabolic health (33), which 
may possibly be explained by a shorter overnight fasting 
duration and excess energy intake. Also, experimental 
circadian misalignment has been shown to lead to 
decreased glucose tolerance (34, 35). Less pronounced 
cases of circadian misalignment could be the result of 
shorter overnight fasting durations.
The present study points to an association between 
weekday of examination and glucose metabolism. This 
finding may be due to different weekend behavior, 
for example, different sleeping and eating patterns, 
compared to weekdays (25). Therefore, examining 
the participants on the same day of the week in 
studies with repeated measurements seems prudent 
when logistically possible; however, studies with 
randomised day of examination are needed to confirm 
the results.
Conclusion
We found that longer fasting duration is associated 
with slightly higher 2-h glucose and insulin levels and 
greater GIP and GLP-1 response after glucose ingestion. 
Additionally, we found higher fasting insulin levels and 
similar fasting glucose levels on Mondays compared to 
the other days of the week pointing to a worse glucose 
regulation after the weekend.
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